PLACENTAL GROWTH FACTOR IN PREDICTING ADVERSE MATERNAL OUTCOMES IN PATIENTS OF HYPERTENSIVE DISORDERS OF PREGNANCY
Not Applicable
- Conditions
- Health Condition 1: O111- -2146826259Health Condition 2: O139- Gestational [pregnancy-induced] hypertension without significant proteinuria, unspecified trimesterHealth Condition 3: O140- Mild to moderate pre-eclampsiaHealth Condition 4: O100- Pre-existing essential hypertension complicating pregnancy, childbirth and the puerperium
- Registration Number
- CTRI/2023/11/059368
- Lead Sponsor
- DR RAKSHITHA RAGHAVENDRA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
WOMEN BETWEEN THE AGES OF 18 AND 45 WHO PRESENTED WITH HYPERTENSIVE DISORDERS OF PREGNANCY BETWEEN 28 AND 40 WEEKS OF PREGNANCY WHILE CARRYING A LIVE, SINGLETON FOETUS
THE HYPERTENSIVE DISORDERS BEING:
1) PRE ECLAMPSIA
2) CHRONIC HYPERTENSION
3) CHRONIC HYPERTENSION WITH SUPERIMPOSED PRE ECLAMPSIA
4) GESTATIONAL HYPERTENSIO
Exclusion Criteria
1) WOMEN WITH PRE DIAGNOSED ECLAMPSIA
2) WOMEN WITH MULTIFETAL GESTATION
3) WOMEN BEARING FETUSES WITH INTRA UTERINE DEMISE
4) WOMEN WITH FETUSES BEARING CONGENITAL ANOMALIES
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TO ASSESS THE CORRELATION BETWEEN CIRCULATING LEVELS OF SERUM PLACENTAL GROWTH FACTOR IN HYEPRTENSIVE GESTATIONAL WOMEN WITH ADVERSE MATERNAL OUTCOMES AND TO ESTABLISH THE NEED FOR PLACENTAL GROWTH FACTOR AS A SEVERITY MARKER IN ASSESSING ADVERSE MATERNAL OUTCOMESTimepoint: APRIL 2023 TO DECEMBER 2024
- Secondary Outcome Measures
Name Time Method SECONDARY OUTCOME MEASURES THE COST EFFECTIVENESS IN DIAGNOSING ADVERSE MATERNAL OUTCOMES AND TO ESTABLISH THE NEED FOR PLACENTAL GROWTH FACTOR AS A SEVERITY MARKER IN ASSESSING ADVERSE MATERNAL OUTCOMESTimepoint: APRIL 2023 TO DECEMBER 2024